Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Vivoryon Therapeutics News

    0,657 € -13,44% -0,102 €
    30.04.24 23:01:00 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QJV6
    ISIN: NL00150002Q7
    US-Symbol: PRBGF
    Typ: Aktie

    Vivoryon Therapeutics News

    24.04.24 - GlobeNewswire
    Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
    Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
    16.04.24 - GlobeNewswire
    Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
    Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
    15.03.24 - GlobeNewswire
    Vivoryon Therapeutics N.V. Announces Changes to Board Composition
    Vivoryon Therapeutics N.V. Announces Changes to Board Composition
    04.03.24 - ARIVA.DE Redaktion
    Vivoryon und der Rückschlag in der Alzheimer-Forschung: Ein detaillierter Blick auf die VIVIAD-Studie
    Ein weiterer Rückschlag für die Alzheimer-​Forschung: Die VIVIAD-​Studie von Vivoryon Therapeutics konnte die gesetzten Ziele nicht erreichen. Was bedeutet dies für die Zukunft der ...
    04.03.24 - GodmodeTrader
    VIVORYON - Studienflop! Biotech-Aktie crasht über 80 %
    04.03.24 - Der Aktionär
    Vivoryon: Alzheimer‑Studie enttäuscht – Aktie bricht ein
    04.03.24 - GlobeNewswire
    Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
    Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ’ s Disease
    08.01.24 - GlobeNewswire
    Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
    Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
    06.12.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
    Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
    28.11.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
    Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
    07.09.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
    Vivoryon Therapeutics N.V. Reports H1 202 3 Financial Results and Highlights Operational Progress
    31.08.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
    Vivoryon Therapeutics N.V. t o Report Half Year 202 3 Financial Results and Operational Progress on September 07 , 202 3
    04.08.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
    Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board , Being H eld on September 15, 2023
    04.08.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
    Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
    16.07.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
    Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-​Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
    21.06.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
    Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
    15.06.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. Announces CEO Transition Plan
    Vivoryon Therapeutics N.V. Announces CEO Transition Plan
    01.06.23 - GlobeNewswire
    Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
    Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
    26.05.23 - GlobeNewswire
    Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
    NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, ...
    25.05.23 - GlobeNewswire
    Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
    NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, ...

    Newssuche

    Videos

    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »